Abstract: An arrangement for the sterile handling of a non-sterile endoscope in a sterile environment comprises a sterile endoscope sheath for accommodating the endoscope and a cable via which the endoscope is connectable to a control unit, the arrangement further comprising a sterile cable sheath for accommodating at least a portion of the cable, wherein the endoscope sheath comprises a first sterile lock comprising at least one first sterile flap which in the closed state shields the endoscope arranged in the endoscope sheath in a sterile manner. The cable sheath comprises a second sterile lock having a second sterile flap which in a closed state shields the cable arranged in the cable sheath and/or a plug connector present on the arranged cable in a sterile manner.

Abstract: An arrangement for the sterile handling of a non-sterile endoscope in a sterile environment comprises a sterile endoscope sheath for accommodating the endoscope and a cable via which the endoscope is connectable to a control unit, the arrangement further comprising a sterile cable sheath for accommodating at least a portion of the cable, wherein the endoscope sheath comprises a first sterile lock comprising at least one first sterile flap which in the closed state shields the endoscope arranged in the endoscope sheath in a sterile manner. The cable sheath comprises a second sterile lock having a second sterile flap which in a closed state shields the cable arranged in the cable sheath and/or a plug connector present on the arranged cable in a sterile manner.

Abstract: A method for treatment of benign prostate hyperplasia, prostate cancer, estrogen-dependent breast cancer, endometrial cancer, ovarian cancer, endometriosis and precocious puberty, or for use for contraceptive purposes or in an in vitro fertilization programme, or for treatment of sex offenders is provided. The method comprises the administration by subcutaneous or intramuscular injection of a therapeutically effective amount of an injectable pharmaceutical composition comprising a solution of a GnRH antagonist peptide according to general formula 1 or a pharmaceutically acceptable salt thereof in a concentration of 0.3-120 mg/ml. Also a pharmaceutical composition and a pharmaceutical kit of parts are provided.

Abstract: A method for treatment of benign prostate hyperplasia, prostate cancer, estrogen-dependent breast cancer, endometrial cancer, ovarian cancer, endometriosis and precocious puberty, or for use for contraceptive purposes or in an in vitro fertilization programme, or for treatment of sex offenders is provided. The method comprises the administration by subcutaneous or intramuscular injection of a therapeutically effective amount of an injectable pharmaceutical composition comprising a solution of a GnRH antagonist peptide according to general formula 1 or a pharmaceutically acceptable salt thereof in a concentration of 0.3-120 mg/ml. Also a pharmaceutical composition and a pharmaceutical kit of parts are provided.

Abstract: Pharmaceutical compositions are provided for the treatment of steroid-dependent and other diseases. The compositions are solutions for subcutaneous or intramuscular injection, and the active agent is a GnRH antagonist peptide according to general formula (1): Ac-DNal-DCpa-DPal-Ser-Aph(X1)-DAph(X2)-Leu-Lys(iPr)-Pro-DAla-NH2 present at a concentration sufficient to from a gel following administration.

Abstract: A method for treatment of benign prostate hyperplasia, prostate cancer, estrogen-dependent breast cancer, endometrial cancer, ovarian cancer, endometriosis and precocious puberty, or for use for contraceptive purposes or in an in vitro fertilization programme, or for treatment of sex offenders is provided. The method comprises the administration by subcutaneous or intramuscular injection of a therapeutically effective amount of an injectable pharmaceutical composition comprising a solution of a GnRH antagonist peptide according to general formula 1 or a pharmaceutically acceptable salt thereof in a concentration of 0.3-120 mg/ml. Also a pharmaceutical composition and a pharmaceutical kit of parts are provided.

Abstract: The invention relates to medicament excipient particles which are suitable for tissue-specific application of a medicament, especially to the central nervous system (CNS). The invention particles can be loaded with or be free pf the active substance. At least one detection protein is bonded to the particle surface or alternatively, the particle surface is modified in such a way that a detection protein bonds with it on contact.